How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies
- PMID: 28388714
- PMCID: PMC5464309
- DOI: 10.1093/neuonc/nox041
How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies
Comment on
-
Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.Neuro Oncol. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030. Neuro Oncol. 2017. PMID: 28388713 Free PMC article. No abstract available.
References
-
- Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. conclusive results of a randomized phase III trial by the EORTC brain & RT groups and NCIC clinical trials group. Proc ASCO:Abstract 2, 2004.
-
- Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
